Condition: Metabolic Dysfunction-Associated Steatotic Liver Disease · Hepatocellular Carcinoma · Metabolic Dysfunction-Associated Steatohepatitis · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
The BOMASH study is a single-center, prospective/retrospective observational study without pharmacological interventions. It will include all patients diagnosed with Metabolic-Associated Steatotic Liver Disease (MASLD/MASH), whether newly diagnosed or previously identified at the center during follow-up or as part of routine diagnostic and therapeutic care. The aim of the study is to identify predictive factors related to the prognosis of patients with metabolic liver disease (MASLD/MASH). Specifically, the study seeks to uncover biomarkers that can identify individuals at risk of requiring a liver transplant or developing HCC.
This description comes directly from the study's public registry record.
Fabio Piscaglia, MD · +39 051 2142542 · fabio.piscaglia@unibo.it
Federico Ravaioli, MD PhD · +39 0512142717 · f.ravaioli@unibo.it
Always discuss trial participation with your own doctor first.
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | Bologna, Bologna, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06813508